🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#SABCS24 Icro Meattini presents interim analysis of the Europa trial. Older women with stage I lo KI67. HR+ BC Rand to RT vs ET. 24 mo FU. No recurrences yet. RT less toxic, 12% stopped ET. 850 enrolled, need more data and longer FU. Pub today in lancet oncol. OncoAlert

Presented in general session 2 of #SABCS24 by super Icro Meattini 🇮🇹 results of the interim analysis of the #EUROPA trial simultaneously published in The Lancet Oncology…really proud for the chance to contribute with Università di Genova Ospedale San Martino Genova 👏🔝💪🔥 OncoAlert SABCS

SUPREMO—post mastectomy radiation in moderate risk breast cancer—does not improve OS, DMFS, and had only an insignificant reduction in 10-yr chest wall recurrence (<2%) #SABCS24 OncoAlert

Omission of Axillary surgery continues to build momentum Here in pts w/ cN0 T1-2 invasive breast cancer—omission is noninferior to SLNB w 6 years med f/u Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial nejm.org/doi/full/10.10… #SABCS24 @GBG_Forschung

EBCTCG Analysis on Obesity Distant recurrence rate ratio in 5 BMI groups, RR=1.06 RR 1.17 obese vs lean In N+: 4% difference in obese vs lean, N0: 2% difference in 10 yr distant risk recurrence SABCS #SABCS24 OncoAlert

Micromets after neoadjuvant portend a worse prognosis and we need to develop a subtype-specific approach. #SABCS24 @GBG_Forschung OncoAlert

ZEST—a ph3 trial for TNBC w/ ctDNA screening 🛑stopped early due to low randomization 🩻 50% with mets at time ctDNA+ ⏲️ ctDNA+ occurred often on 1st test/ ≤6 mos from EoT ▫️Recurrence-free interval longer w/ niraparib, but not powered for endpoint #SABCS24 OncoAlert

Out our paper on Cell Metabolism about phase II BREAKFAST trial in pts w/early TNBC (n=30) Francesca Ligorio Istituto Tumori: 🔹Cyclic Fasting-Mimicking Diet (FMD)+AC-T achieved remarkable pCR rate (56.6%)–even w/o platinum or pembro 🔹 Glucose metabolism downmodulation predicts pCR

2024 approvals: Summary of 6 new drugs/indications in #SkinCancer, #ThyroidCancer, #Sarcoma, and #Glioma by U.S. FDA 1. #Lifileucel 2. #Selpercatinib 3. #AfamiCel 4. #Vorasidenib 5. #Cosibelimab #OncTwitter #MedTwitter #Cancer #Oncology #Melanoma

A lovely sun pillar in Hershey PA this evening

Promoting healthy aging in women. Prolonging ovarian life. Slowing the onset of menopause. A feature @nature nature.com/articles/d4158… open-access And this week's editorial nature.com/articles/d4158…

SBRT in Oligometastatic CRPC: ☢️Adding SBRT to ADT+Enza doubled rPFS and delayed time to next therapy. OS data immature but signals lower risk of death. Minimal toxicity. ☢️Should SBRT become standard in oligometastatic CRPC? ASCO OncoAlert #GU25 #cancer #oncology

Phase 2 #STAMPEDE trial: tE2 patches + ARPI vs. LHRHa + ARPI in met #prostatecancer - similar PSA responses in both groups, confirming tE2’s efficacy. Effective ADT with better side effect profile! #NicholasJames #RuthLangley ASCO #GU25 OncoAlert

Perioperative durvalumab + NAC significantly improves EFS and OS, reducing metastasis! Benefit seen in both pCR and non-pCR, reinforcing durvalumab as a potential new SOC for patients with MIBC! Matt Galsky Tom Powles #GU25 ASCO OncoAlert

Congratulations Wilmot Cancer Institute ! Penn State when are we gonna do it ?

Congratulations! Well done ! We know how hard it is because we tried unsuccessfully! Big day ! Ruth O'Regan

FDA approves a treatment for adult patients with unresectable or metastatic hepatocellular carcinoma fda.gov/drugs/resource…

Read how Dana-Farber, we embarked with KaelinLab on a journey from basic lab experiments to late stage clinical trial that led to the approval of the 1st HIF-2 inhibitor in kidney cancer! All while KaelinLab et al received The Nobel Prize for their discovery This is what

What an amazing celebration of #lcsm legend, Dr. Chandra P Belani MD ‘s impactful career organized by no other than the true Ram-bo of today’s oncology Suresh S. Ramalingam, MD, FASCO! My oncology career started memorizing all the Belani et al papers- today’s oncology fellows memorize papers of Chandra’s

📌 Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer (OASIS-4 phase 3 trial) 🔗nej.md/3FnKwU7 #ASCO25 OncoAlert #OncoAlertAF NEJM